Gordon Parry

USPTO Granted Patents = 12 (Patent Applications = 6)

CIPO Patents = 1 (Patent Applications = 2)

EPO Patents = 4 (Patent Applications = 3)

Average Co-Inventor Count = 6.1

ph-index = 4

Forward Citations = 61(Granted Patents)

Location History:

Walnut Creek, CA (US) (2004)
Oakland, CA (US) (2007 - 2022)

Company Filing History:

6 out of 192

Bayer Schering Pharma Ag

patents

5 out of 114

Laboratory Corporation of America Holdings

patents

1 out of 1,384

Schering Aktiengesellschaft

patents

Years Active: 2004-2022

Loading Chart...

12 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11401344 - Methods for determining the likelihood of survival and for predicting likelihood of metastasis in cancer patients (2022-08-02),

2. 10775382 - Methods of determining patient response by measurement of HER-3 (2020-09-15),

3. 9766242 - Methods of determining patient response by measurement of HER-3 and P95 (2017-09-19),

4. 9110066 - HER-3 antibodies and methods of use (2015-08-18),

5. 8349574 - Methods of determining patient response by measurement of Her-3 (2013-01-08),

6. 7893217 - Isolated human antibodies that bind epitopes on RG1 (2011-02-22),

7. 7887804 - Methods for treating disease-states associated with RG1 using immunoconjugates (2011-02-15),

8. 7611706 - RG1 antibodies and uses thereof (2009-11-03),

9. 7608263 - RG1 antibodies and uses thereof (2009-10-27),

10. 7335748 - RG1 antibodies and uses thereof (2008-02-26),

11. 7307154 - DNA encoding a novel RG1 polypeptide (2007-12-11),

12. 6682902 - DNA encoding a novel RG1 polypeptide (2004-01-27),

Title: The Innovative Mind of Gordon Parry: A Pioneer in Cancer Research

Introduction: Gordon Parry, a prolific inventor based in Oakland, CA (US), has made significant contributions to the field of cancer research with his groundbreaking inventions. With a total of 12 patents to his name, Parry's work has revolutionized the way we approach cancer treatment and patient care.

Latest Patents:

1. Methods for determining the likelihood of survival and for predicting the likelihood of metastasis in cancer patients: This patent focuses on accurately quantifying HER2 and/or p95 expression in subjects with HER2 positive cancer, providing crucial insights into the risk of brain relapse in such patients.

2. Methods of determining patient response by measurement of HER-3: Parry's invention offers innovative methods for measuring and quantifying the presence and amount of Her-3 in samples, along with the development of specific antibodies for Her-3 detection.

Career Highlights: Parry has made significant contributions during his tenure at companies such as Bayer Schering Pharma AG and Laboratory Corporation of America Holdings. His innovative approach to cancer research has led to the development of cutting-edge technologies that are shaping the future of healthcare.

Collaborations: Throughout his career, Parry has collaborated with esteemed professionals in the field, including Richard N Harkins and Deborah Parkes. Together, they have worked towards advancing cancer diagnostics and treatment options, emphasizing the importance of interdisciplinary teamwork in driving innovation.

Conclusion: Gordon Parry's exceptional work as an inventor and researcher in the field of cancer research has paved the way for new and improved methods of diagnosis, treatment, and patient care. His dedication to innovation and collaboration underscores the transformative impact of his work, making him a true pioneer in the field.

This text is generated by artificial intelligence and may not be accurate.